SPACEMED-X (formally Cardix Therapeutics) was founded in 2016 in the United States. The company is at the forefront of developing an innovative patented drug designed to improve cardiac function by increasing heart rate and cardiac output. Currently, no regulatory-approved medicines of this type are available in the United States or worldwide. SPACEMED-X’s groundbreaking drug aims to fill this void, offering a unique and potentially transformative solution to those facing cardiac challenges, particularly in the demanding context of space exploration and multi-planet colonization.

The novel drug developed by SPACEMED-X presents an alternative to traditional pacemakers, emphasizing non-invasive methodology and the absence of electrical interference. This pioneering approach could be especially well-suited for space and multi-planet activities, where invasive procedures and dependence on electronic devices can introduce significant risks and logistical challenges. By offering a rapid, safe, and effective means of enhancing cardiac function, SPACEMED-X’s drug can support astronauts can pursue their missions, and space colonizers can flourish in their new environments. In this capacity, the innovative drug has the potential to play a pivotal role in the successful expansion of human civilization beyond Earth, contributing to a brighter future for interstellar exploration and settlement.